3/26
01:49 pm
dnli
Denali Therapeutics (DNLI) had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an "overweight" rating on the stock.
Low
Report
Denali Therapeutics (DNLI) had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an "overweight" rating on the stock.
3/26
11:52 am
dnli
Denali Therapeutics (DNLI) had its price target raised by The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "buy" rating on the stock.
3/26
10:49 am
dnli
Denali Therapeutics (DNLI) had its price target raised by Stifel Nicolaus from $34.00 to $41.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by Stifel Nicolaus from $34.00 to $41.00. They now have a "buy" rating on the stock.
3/26
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $36.00 to $38.00. They now have a "buy" rating on the stock.
High
Report
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $36.00 to $38.00. They now have a "buy" rating on the stock.
3/26
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $29.00 to $32.00. They now have an "outperform" rating on the stock.
High
Report
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $29.00 to $32.00. They now have an "outperform" rating on the stock.
3/26
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by HC Wainwright from $32.00 to $42.00. They now have a "buy" rating on the stock.
High
Report
Denali Therapeutics (DNLI) had its price target raised by HC Wainwright from $32.00 to $42.00. They now have a "buy" rating on the stock.
3/26
06:58 am
dnli
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript [Seeking Alpha]
Low
Report
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript [Seeking Alpha]
3/25
05:18 pm
dnli
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost [Yahoo! Finance]
High
Report
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost [Yahoo! Finance]
3/25
11:50 am
dnli
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Medium
Report
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
3/24
10:00 am
dnli
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
Low
Report
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
3/19
11:11 am
dnli
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts [Yahoo! Finance]
Low
Report
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts [Yahoo! Finance]
3/15
07:26 am
dnli
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build [Yahoo! Finance]
Low
Report
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build [Yahoo! Finance]
3/13
04:22 pm
dnli
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? [Yahoo! Finance]
Neutral
Report
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? [Yahoo! Finance]
3/13
12:54 am
dnli
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains [Yahoo! Finance]
Low
Report
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains [Yahoo! Finance]
3/2
08:02 pm
dnli
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/2
08:03 am
dnli
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
2/26
04:22 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
2/26
04:01 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Low
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2/23
06:01 pm
dnli
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
2/19
08:30 am
dnli
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Medium
Report
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
2/6
08:04 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Medium
Report
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
2/5
02:00 pm
dnli
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Low
Report
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
2/4
06:33 am
dnli
How Denali's Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors [Yahoo! Finance]
Medium
Report
How Denali's Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors [Yahoo! Finance]
2/2
08:13 am
dnli
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ [Yahoo! Finance]
Medium
Report
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ [Yahoo! Finance]
2/2
08:00 am
dnli
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Medium
Report
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™